The story of Viagra presents a complex picture for those considering investment. While the initial launch generated substantial gains, the lapse of its patent opened the door to cheaper versions, dramatically reducing market share. This presents a particular risk for pharmaceutical companies relying on related blockbuster medications, suggesting th

The story of Viagra, and its developer copyright, presents a complex case study for investors. At first a blockbuster drug, yielding billions in sales , its intellectual property lapse created a flood of lower-priced alternatives , significantly eroding its market share . While specific pharmaceutical companies may try to capitalize on similar cond